Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Vaxneuvance
Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed) · Abschnitt 4.5 · PDF-Seite 5
HOS-147676 · Präparat HOS-099718
Data from a post-marketing clinical study evaluating the impact of prophylactic use of antipyretics
(ibuprofen and paracetamol) on the immune response to other pneumococcal vaccines suggest that
administration of antipyretics concomitantly or within the same day of vaccination may reduce the
immune response after the infant series. Responses to the booster dose administered at 12 months were
unaffected. The clinical significance of this observation is unknown.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-16T14:19:00Z · SHA-256 8c806efad2c6480965326c02c35aa390b1a5f1070feca6a9495a17a403d294b7 · Passage f01a5fedff819ba44c7e0db5ff2ba9cd92113f1477550de00d007823abcdf3d2 · Zeichen 682–1146 im Abschnitt
Wechselwirkungen · Wezenla
WEZENLA 130 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7
HOS-151578 · Präparat HOS-100575
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs,
6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:50:00Z · SHA-256 ee8a4a8f48f02ce6abe6b0d6d8b9c74092ca858a6dbb9266fd0c8cbbf48dea12 · Passage 1160a00c4608f29067bc36e867879ffd80cb08b3f41e1bf69a2923a3206527c8 · Zeichen 498–1526 im Abschnitt
Wechselwirkungen · Wezenla
WEZENLA 45 mg solution for injection WEZENLA 45 mg solution for injection in pre-filled syringe WEZENLA 90 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 28
HOS-151625 · Präparat HOS-100575
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs,
6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:50:00Z · SHA-256 ee8a4a8f48f02ce6abe6b0d6d8b9c74092ca858a6dbb9266fd0c8cbbf48dea12 · Passage 1160a00c4608f29067bc36e867879ffd80cb08b3f41e1bf69a2923a3206527c8 · Zeichen 498–1526 im Abschnitt
Wechselwirkungen · Wezenla
WEZENLA 45 mg solution for injection in pre-filled pen WEZENLA 90 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 55
HOS-151658 · Präparat HOS-100575
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs,
6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:50:00Z · SHA-256 ee8a4a8f48f02ce6abe6b0d6d8b9c74092ca858a6dbb9266fd0c8cbbf48dea12 · Passage 509d6d92dbc48f1b359d8b9cd57701ef0c13ee00b8d9b7ec2dd79e7280071ea4 · Zeichen 498–1393 im Abschnitt
Wechselwirkungen · Pyzchiva
Pyzchiva 130 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 6
HOS-151980 · Präparat HOS-100665
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-
mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T14:40:00Z · SHA-256 24f42a13e263361e45daf03240bd1f30ff701ef234e4b135f72f1f3a44cecfae · Passage d7992329e08441a34876eaaebb05cd7e3c6d36484de465d2bb947d8ed5148c63 · Zeichen 502–1531 im Abschnitt
Wechselwirkungen · Pyzchiva
Pyzchiva 45 mg solution for injection Pyzchiva 45 mg solution for injection in pre-filled syringe Pyzchiva 90 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 25
HOS-152001 · Präparat HOS-100665
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-
mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T14:40:00Z · SHA-256 24f42a13e263361e45daf03240bd1f30ff701ef234e4b135f72f1f3a44cecfae · Passage d7992329e08441a34876eaaebb05cd7e3c6d36484de465d2bb947d8ed5148c63 · Zeichen 560–1589 im Abschnitt
Wechselwirkungen · Pyzchiva
Pyzchiva 45 mg solution for injection in pre-filled pen Pyzchiva 90 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 49
HOS-152023 · Präparat HOS-100665
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-
mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T14:40:00Z · SHA-256 24f42a13e263361e45daf03240bd1f30ff701ef234e4b135f72f1f3a44cecfae · Passage d7992329e08441a34876eaaebb05cd7e3c6d36484de465d2bb947d8ed5148c63 · Zeichen 502–1531 im Abschnitt
Wechselwirkungen · Yesintek
Yesintek 130 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 6
HOS-153005 · Präparat HOS-100897
. In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab
was explored. There were no indications of an interaction with these concomitantly administered
medicinal products. The basis for this analysis was that at least 100 patients (> 5% of the studied
population) were treated concomitantly with these medicinal products for at least 90% of the study
period. The pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX,
NSAIDs, 6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis,
Crohn’s disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic
arthritis or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or
vedolizumab) in patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-27T10:20:00Z · SHA-256 c2eb149e2f8e0a36b990a48a3a15fc1d527af61bdadc18d590f9ad1e30614e1b · Passage 2ca429d3b4591459067155947c799197b31aff6ebde080389c94b696cb23735d · Zeichen 502–1532 im Abschnitt
Wechselwirkungen · Yesintek
Yesintek 45 mg solution for injection Yesintek 45 mg solution for injection in pre-filled syringe Yesintek 90 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 25
HOS-153028 · Präparat HOS-100897
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab
was explored. There were no indications of an interaction with these concomitantly administered
medicinal products. The basis for this analysis was that at least 100 patients (> 5% of the studied
population) were treated concomitantly with these medicinal products for at least 90% of the study
period. The pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX,
NSAIDs, 6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis,
Crohn’s disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic
arthritis or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or
vedolizumab) in patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-27T10:20:00Z · SHA-256 c2eb149e2f8e0a36b990a48a3a15fc1d527af61bdadc18d590f9ad1e30614e1b · Passage f568248ef36dec77b2ecb9c4fe7aa87ca2d134d3394ab630e9506f004a5f1ccc · Zeichen 502–1530 im Abschnitt
Wechselwirkungen · Yesintek
Yesintek 45 mg solution for injection in pre-filled pen Yesintek 90 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 50
HOS-153051 · Präparat HOS-100897
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-
mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-27T10:20:00Z · SHA-256 c2eb149e2f8e0a36b990a48a3a15fc1d527af61bdadc18d590f9ad1e30614e1b · Passage d7992329e08441a34876eaaebb05cd7e3c6d36484de465d2bb947d8ed5148c63 · Zeichen 499–1528 im Abschnitt
Wechselwirkungen · Usymro
Usymro 130 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7
HOS-153101 · Präparat HOS-100925
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-
mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-06T13:10:00Z · SHA-256 274a2e52e504e4f872783b2297b7ce22f2f8fa38a366b8eaea4a5c9ad8e0746b · Passage d7992329e08441a34876eaaebb05cd7e3c6d36484de465d2bb947d8ed5148c63 · Zeichen 552–1581 im Abschnitt
Wechselwirkungen · Usymro
Usymro 45 mg solution for injection Usymro 45 mg solution for injection in pre-filled syringe Usymro 90 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 30
HOS-153131 · Präparat HOS-100925
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-
mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-06T13:10:00Z · SHA-256 274a2e52e504e4f872783b2297b7ce22f2f8fa38a366b8eaea4a5c9ad8e0746b · Passage 24b84bd75e5058db15b93f293c08855c964f407176ac5b86198d1ae410d0defe · Zeichen 497–1286 im Abschnitt
Wechselwirkungen · Usgena
Usgena 130 mg concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 6
HOS-153936 · Präparat HOS-101078
In the population pharmacokinetic analyses of the ustekinumab phase 3 studies, the effect of the most
frequently used concomitant medicinal products in patients with psoriasis (including paracetamol,
ibuprofen, acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of
ustekinumab was explored. There were no indications of an interaction with these concomitantly
administered medicinal products. The basis for this analysis was that at least 100 patients (> 5% of the
studied population) were treated concomitantly with these medicinal products for at least 90% of the
study period. The pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX,
NSAIDs, 6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis,
Crohn’s disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic
arthritis or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or
vedolizumab) in patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-11T11:11:01Z · SHA-256 8e5be544de91a74438b6084c7497550446fa3104ba8f5e5368034aaef5a300fc · Passage a4e74367436bc70e7f0770536f5b4653b9431f3d443db9493b0e7e9218d7b0fd · Zeichen 515–1555 im Abschnitt
Wechselwirkungen · Usgena
Usgena 45 mg solution for injection Usgena 45 mg solution for injection in pre-filled syringe Usgena 90 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 29
HOS-153965 · Präparat HOS-101078
In the population pharmacokinetic analyses of the ustekinumab phase 3 studies, the effect of the most
frequently used concomitant medicinal products in patients with psoriasis (including paracetamol,
ibuprofen, acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of
ustekinumab was explored. There were no indications of an interaction with these concomitantly
administered medicinal products. The basis for this analysis was that at least 100 patients (> 5% of the
studied population) were treated concomitantly with these medicinal products for at least 90% of the
study period. The pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX,
NSAIDs, 6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis,
Crohn’s disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic
arthritis or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or
vedolizumab) in patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-11T11:11:01Z · SHA-256 8e5be544de91a74438b6084c7497550446fa3104ba8f5e5368034aaef5a300fc · Passage a4e74367436bc70e7f0770536f5b4653b9431f3d443db9493b0e7e9218d7b0fd · Zeichen 515–1555 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.